Книги з теми "Opioid activity"
Щоб переглянути інші типи публікацій з цієї теми, перейдіть за посиланням: Opioid activity.
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-25 книг для дослідження на тему "Opioid activity".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте книги для різних дисциплін та оформлюйте правильно вашу бібліографію.
1
Ahmad, Iftikhar. Pro and anticonvulsant activity of opioid analgesics and their interaction with propofol. Manchester: University of Manchester, 1994.
Знайти повний текст джерела
2
Gelbspan, Ross. The heat is on: The high stakes battle over Earth's threatened climate. Reading, Mass: Addison-Wesley Pub. Co., 1997.
Знайти повний текст джерела
3
Gelbspan, Ross. The heat is on: The climate crisis, the cover-up, the prescription. Reading, Mass: Perseus Books, 1998.
Знайти повний текст джерела
4
Kulkarni, Sandhya N. Synthesis and opioid activity of dynorphin analogues with the modifications in the message sequence. 1995.
Знайти повний текст джерела
5
McFadyen, Iain James. Structure-activity relationships of opioid ligands. 1999.
Знайти повний текст джерела
6
Snyder, Kristin Renee. Synthesis and opioid activity of dynorphin a analogues. 1993.
Знайти повний текст джерела
7
Pham, Thien C., Courtney Kominek, Abigail Brooks, and Jeffrey Fudin. Opioid Pharmacotherapies for Chronic Pain (DRAFT). Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190265366.003.0014.
Повний текст джерелаАнотація:
Chronic pain management employing opioids is divided into subtopics, including: risk–benefit balance; a review of the mode of action of opioid analgesics (Chap. 8); the suitability of synthetic opioids for neuropathic pain; endocrinopathy proceeding from opioid use; the use of the morphine-equivalent daily dose as a conversion tool for managing multiple opioids; the place of extended-release and long-acting opioids; current technology in abuse deterrence; and an overview of the challenges entailed in prescribing. This last section details the complex components of a decision to prescribe opioids for chronic pain. A table is provided of the classification of common opioid analgesics and their duration of activity. A text box gives the table of contents of Appendix B, supportive tables and figures therein for this chapter; there is also a text box listing additional resources.
8
Sjøgren, Per, Frank Elsner, and Stein Kaasa. Non-opioid analgesics. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199656097.003.0096.
Повний текст джерелаАнотація:
Non-opioid analgesics encompass the non-steroidal anti-inflammatory drugs (NSAIDs) and paracetamol (acetaminophen). The NSAIDs include acetylsalicylic acid (ASA, aspirin), dipyrone (metamizole), and numerous other drugs in diverse classes. The NSAIDs have potent anti-inflammatory, analgesic and antipyretic activity, and are among the most widely used drugs worldwide. In palliative medicine, they represent the first step of the World Health Organization’s analgesic ladder used for mild pain and they are an important supplement to opioids and adjuvant drugs at higher steps of the ladder. The disadvantages of non-opioid analgesics include a ceiling effect for pain relief and the risk of side effects. NSAIDs are also associated with an increased risk of adverse gastrointestinal, renal, and cardiovascular effects and hepatotoxicity can result from overdosing with paracetamol. This chapter describes the clinical pharmacology of NSAIDs, their classification, molecular mechanisms of action and adverse effects, as well as some recent developments aimed at designing effective anti-inflammatory agents with improved safety and tolerability profiles.
9
Arttamangkul, Seksiri. Synthesis and opioid activity of conformationally constrained dynorphin A analogues. 1995.
Знайти повний текст джерела
10
Nutt, David J., and Liam J. Nestor. The opioid system and addiction. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198797746.003.0010.
Повний текст джерелаАнотація:
The opioid system of the brain is the major target for opiate drugs such as morphine and heroin, and has been implicated in processes such as pain, stress and reward. Many of these effects take place at the mu opioid receptor (mOR), which is distributed throughout the brain. Significantly, genetic polymorphisms at the mOR may confer a greater dopamine response to the reinforcing effects of alcohol, and it has been suggested that addiction per se may be associated with alterations to the opioid system. There is evidence for the potential efficacy of mOR antagonists (e.g. naltrexone) in reducing drug and alcohol relapse, increasing treatment retention and attenuating the subjective effects of substances of abuse. Medications with partial agonist activity at the kappa opioid receptor (e.g. nalmefene) may also confer an additional clinical advantage by reducing binging following relapse.
11
Cavacuiti, Christopher. The Pharmacology of Opioids (DRAFT). Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190265366.003.0008.
Повний текст джерелаАнотація:
This chapter focuses on the attributes of and component medications within the class of opioids, emphasizing kinetics, dynamics, and therapeutic and adverse effects. To help patients make informed decisions about opioid use, the clinicians prescribing these medications must be able to explain when opioids are likely to help and when they are likely to do harm. Subclasses of opioids include phenanthrenes, benzomorphans, phenylpiperidines, and diphenylheptanes; examples are given of each, with respective utilities and limitations. A discussion then follows of pharmacodynamics, pharmacokinetics, opioid receptor affinity, metabolism, and drug interactions. Tables and figures amplifying the text include: opioid class by synthetic method (Table 8.1); common physiological effects by opioid receptor subtypes (Table 8.2); opioid activity (Table 8.3); and a listing of figures and tables located in Appendix B (opioid receptor affinity, respiratory depression with opioids, adverse effects, metabolism, pharmacogenetics, extended release/long-acting opioids, abuse deterrent formulations). A text box provides supplemental resources.
12
Cheatle, Martin D. Managing Pain in Patients with a History of a Substance Use Disorder. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199981830.003.0008.
Повний текст джерелаАнотація:
Patients with chronic pain tend to be complex and can present with multiple comorbidities, including anxiety, depression, functional disabilities, and substance misuse or abuse. The burgeoning rate of prescription opioid misuse and abuse and opioid-related fatalities has generated a great deal of scholarly activity on understanding the etiology of opioid misuse/abuse and developing risk assessment and mitigation strategies to curb this public health crisis. Balancing effective pain management and reducing the risk of opioid misuse/abuse and diversion can be a daunting endeavor, as is controlling pain in patients with pain and concomitant substance use disorders. This chapter provides an overview of the prevalence of opioid misuse/abuse in patients with chronic pain. It covers pharmacologic and nonpharmacologic therapies for patients with pain and co-occurring opioid use disorder and also discusses the challenges and opportunities to improve pain care and reduce misuse and abuse of opioids.
13
Gerhard, Gwenyth Gravlin. THE RELATIONSHIPS AMONG HABITUAL PHYSICAL ACTIVITY, ENDOGENOUS OPIOID LEVELS, AND SUBSEQUENT ACUTE SURGICAL PAIN EXPERIENCES (ENDORPHIN, VISUAL ANALOG SCALING). 1985.
Знайти повний текст джерела
14
Babor, Thomas F., Jonathan Caulkins, Benedikt Fischer, David Foxcroft, Keith Humphreys, María Elena Medina-Mora, Isidore Obot, et al. Health and social services for drug users. Oxford University Press, 2018. http://dx.doi.org/10.1093/oso/9780198818014.003.0009.
Повний текст джерелаАнотація:
Health and social services attempt to reduce drug-related harm by promoting abstinence, by reducing the frequency of drug use, and by changing behaviours that are harmful to drug users and society at large, such as HIV risk behaviour, drug overdose, and criminal activity. Among the most carefully evaluated programmes are interventions focused on users of heroin and other opioids. The documented benefits of opioid substitution therapy include reduced overdose mortality, less HIV infection, and lower crime rates. Therapeutic communities, contingency management, counselling for marijuana dependence, and brief interventions for at-risk drug use have the next strongest level of evidence. Psychosocial interventions for users of cocaine, methamphetamine, hallucinogens, benzopdiazepines, and club drugs have evidence of effectiveness as well.
15
Hamilton, Matthew Lloyd. COMT genotypes in pain responses. Edited by Paul Farquhar-Smith, Pierre Beaulieu, and Sian Jagger. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198834359.003.0080.
Повний текст джерелаАнотація:
The landmark study discussed in this chapter is ‘COMT val158met genotype affects μ-opioid neurotransmitter responses to a pain stressor’, published by Zubieta et al. in 2003. Catechol-O-methyl-transferase (COMT) is a key modulator of dopaminergic and noradrenergic neurotransmission. This study focused on a single nucleotide polymorphism of the COMT gene encoding the substitution of valine (val) by methionine (met) at Codon 158 (val158met), resulting in a three- to fourfold reduction in its activity. Individuals with the val/val genotype have the highest activity of COMT, val/met genotypes have intermediate activity, and met/met genotypes have the lowest activity of COMT. Using a mixture of PET imaging of the binding of μ-opioid receptors and correlation with clinical outcomes, this groundbreaking study provided evidence that confirmed their hypothesis and established the COMT val158met SNP as one of the first gene modifications with direct ramifications on human pain.
16
Wakeman, Sarah E., and Josiah D. Rich. Pharmacotherapy for substance use disorders within correctional facilities. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199360574.003.0046.
Повний текст джерелаАнотація:
Drug addiction treatment is increasingly complex. Only 5% of prisons and 34% of jails offer any detoxification services, and only 1% of jails offer methadone for opioid withdrawal. Even fewer facilities offer medication assisted therapy (MAT) for alcohol or substance use disorders despite the tremendous evidence base supporting the use of medications to treat addiction. Untreated opioid dependence both within corrections and in the community is associated with HIV, Hepatitis C, crime, and death by overdose. Substantial evidence argues that these risks are reduced through long-term treatment with agonist medications such as methadone and buprenorphine. Only a minority of prisoners receive any addiction treatment while incarcerated. Those that do are usually offered behavioral interventions, which when used alone have extremely poor outcomes. Although there are limited studies on the outcomes of drug treatment during incarceration, there are nearly 50 years of evidence documenting the efficacy of methadone given in the community in reducing opioid use, drug-related health complications, overdose, death, criminal activity, and recidivism. Buprenorphine is similarly an effective, safe, and cost-effective long-term treatment for opioid dependence that reduces other opioid use and improves health and quality of life outcomes. There is a growing role for MAT in jails, and to a lesser degree in prisons for the treatment of alcohol and opiate dependence. This chapter presents the current state of evidence based practice in correctional MAT models.
17
Wakeman, Sarah E., and Josiah D. Rich. Pharmacotherapy for substance use disorders within correctional facilities. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199360574.003.0046_update_001.
Повний текст джерелаАнотація:
Drug addiction treatment is increasingly complex. Only 5% of prisons and 34% of jails offer any detoxification services, and only 1% of jails offer methadone for opioid withdrawal. Even fewer facilities offer medication assisted therapy (MAT) for alcohol or substance use disorders despite the tremendous evidence base supporting the use of medications to treat addiction. Untreated opioid dependence both within corrections and in the community is associated with HIV, Hepatitis C, crime, and death by overdose. Substantial evidence argues that these risks are reduced through long-term treatment with agonist medications such as methadone and buprenorphine. Only a minority of prisoners receive any addiction treatment while incarcerated. Those that do are usually offered behavioral interventions, which when used alone have extremely poor outcomes. Although there are limited studies on the outcomes of drug treatment during incarceration, there are nearly 50 years of evidence documenting the efficacy of methadone given in the community in reducing opioid use, drug-related health complications, overdose, death, criminal activity, and recidivism. Buprenorphine is similarly an effective, safe, and cost-effective long-term treatment for opioid dependence that reduces other opioid use and improves health and quality of life outcomes. There is a growing role for MAT in jails, and to a lesser degree in prisons for the treatment of alcohol and opiate dependence. This chapter presents the current state of evidence based practice in correctional MAT models.
18
Bannister, Kirsty. Opioid-induced hyperalgesia. Edited by Paul Farquhar-Smith, Pierre Beaulieu, and Sian Jagger. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198834359.003.0061.
Повний текст джерелаАнотація:
The landmark paper discussed in this chapter is ‘Opioid-induced hyperalgesia: Abnormal or normal pain?’, published by Simonnet and Rivat in 2003. Morphine remains the analgesic of choice for those patients suffering moderate-to-severe pain, but it is increasingly recognized that worsening pain can be associated with chronic opioid consumption—the so-called phenomenon of opioid-induced hyperalgesia (OIH). This paper combined knowledge from clinical studies and experimental evidence from animal research in order to delve deeper into the workings of OIH and ask whether it represented normal or abnormal pain. The authors, intrigued by evidence indicating that exogenous opioids could activate both inhibitory and facilitatory pain systems, looked to reassess the role of such enhancement in pain sensitivity. As the debate regarding the very existence of OIH rages on, we pain specialists can take comfort in the knowledge that for many before us, over a decade ago, the reality of OIH was never in question.
19
Batra, Sonal, Noah Villegas, and Erin Zerbo. Harm Reduction. Edited by Hunter L. McQuistion. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190610999.003.0005.
Повний текст джерелаАнотація:
Harm reduction is defined as a set of policies, programs, and practices aimed at reducing the negative health, social, and economic consequences associated with various behaviors. Although classically applied to the treatment of substance use disorders, its scope has broadened over time to include high-risk sexual activity, nonadherence to treatment, and other behaviors that may lead to negative consequences. In addition to providing relevant historical context for scenarios encountered, this chapter uses a case to demonstrate how a provider might take a nonjudgmental and humanistic approach to identifying maladaptive behaviors and apply evidence-based, realistic interventions to reduce associated harms. Specific topics discussed include opioid use disorder, tobacco use disorder, female sex work, and nonadherence to psychotropic medications.
20
Benning, Stephen D. The Postauricular Reflex as a Measure of Attention and Positive Emotion. Oxford University Press, 2018. http://dx.doi.org/10.1093/oxfordhb/9780199935291.013.74.
Повний текст джерелаАнотація:
The postauricular reflex is a muscular reaction that occurs behind the ear in response to short, abrupt sounds. Its magnitude increases with louder eliciting sounds, rotating the eyes in the direction of the eliciting sound, and flexing the head forward. The reflex exhibits prepulse inhibition, especially during attention to complex foreground stimuli. Its magnitude is larger (or potentiated) during pleasant than during neutral pictures, sounds, and videos that are highly arousing. This pattern is particularly evident for erotic, food, and nurturant scenes, suggesting it assesses more than just appetitive processing. This reflex’s potentiation varies across development; positively correlates with personality traits associated with well-being; and negatively correlates with such psychopathologies as depression, schizophrenia, and opioid dependence. It appears distinct from and uncorrelated with the startle blink reflex. New data suggest that activity in left frontal areas generates postauricular reflex potentiation during pleasant versus neutral pictures.
21
Mease, Philip. Neurobiology of pain in osteoarthritis. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199668847.003.0013.
Повний текст джерелаАнотація:
Significant advances in our understanding of the neurobiology of pain in osteoarthritis (OA) have occurred in the last decade and are herein summarized. Pain is the predominant symptom of OA and occurs at multiple levels from non-cartilage peripheral tissues to spinal cord, and brain and back. At each level, nerve function is regulated by complex ionic channels, neuropeptide expression, and cytokine and chemokine activity. Previously considered a non-inflammatory condition, it is now recognized that cell proliferation and inflammatory cytokine production occurs in OA synovium, contributing to peripheral sensitization. Genetic profile influences nociceptive neuropeptide expression and thus, pain perception. Both peripheral and central sensitizing factors, including increased neuropeptide and microglial activity, lead to pain augmentation and persistence. Pain processing in brain centres such as the somatosensory cortex and insula are influenced by affective areas such as the amygdala. Descending receptor pathways through the midbrain to the dorsal horn, such as norepinephrine, serotonin, opioid, and cannabinoid, normally provide pain inhibitory function but this function may be diminished in chronic pain states such as OA, leading to allodynia and hyperalgesia. Functional neuroimaging has contributed to our understanding of the complex interplay of peripheral and central mechanisms. Recent evidence that grey matter volume decrease in chronic pain states may be reversible (e.g. after pain relief post OA hip arthroplasty) illuminates the potential for central neuroplasticity. Greater understanding of the neurobiology of OA pain provides evidence for therapeutic approaches that address peripheral and/or central pain mechanisms and provides a guide for future targeted pain therapeutics.
22
Popes and Politics: Reform, Resentment, and the Holocaust (Handbooks of Catholic Theology). Continuum International Publishing Group, 2002.
Знайти повний текст джерела
23
Popes And Politics: Reform, Resentment, And The Holocaust. Continuum International Publishing Group, 2004.
Знайти повний текст джерела
24
Borum Chattoo, Caty. Story Movements. Oxford University Press, 2020. http://dx.doi.org/10.1093/oso/9780190943417.001.0001.
Повний текст джерелаАнотація:
Social-issue documentaries are art for civic imagination and social critique. Today, audiences experience documentaries that interrogate topics like sexual assault in the military (The Invisible War), the opioid crisis (Heroin(e)), racial injustice (13th), government surveillance (Citizenfour), animal captivity (Blackfish), and more. Along a continuum of social change, these intimate nonfiction films have changed national conversations, set media agendas, mobilized communities and policymakers, and provided new portals into social problems and lived experiences—accessed by expanding audiences in a transforming dual marketplace that includes mainstream entertainment outlets and grassroots venues. Against the activism backdrop of the participatory networked culture, the contemporary function of social-issue documentaries in civic practice is embodied also in parallel community engagement—the active role of civil society, communities, and individuals—that has dynamically evolved over recent decades. Story Movements: How Documentaries Empower People and Inspire Social Change explores the functions and public influence of social-issue documentary storytelling in the networked era. At the book’s core is an argument about documentary’s vital role in storytelling culture and civic practice with an impulse toward justice and equity. Intimate documentaries illuminate complex realities and stories that disrupt dominant cultural narratives and contribute new ways for publics to contemplate and engage with social challenges. Written by a documentary producer, scholar, and director of the Center for Media & Social Impact, the book features original interviews with award-winning filmmakers and field leaders to reveal the motivations and influence of some of most lauded, eye-opening stories of the evolving documentary age.
25
Winter, Jerrold. Our Love Affair with Drugs. Oxford University Press, 2020. http://dx.doi.org/10.1093/oso/9780190051464.001.0001.
Повний текст джерелаАнотація:
Prescription, illicit, and recreational drugs touch all of our lives yet a basic understanding of these chemicals is largely absent among Americans. Jerrold Winter offers a comprehensive account of psychoactive drugs, chemicals which influence our brains in myriad ways. Manifestations of their influence on the brain are quite varied. There may be the comfort provided by opioids to those who are dying or in pain or, in everyday life, the surge of contentment for the users of caffeine, nicotine, heroin, alcohol, or marijuana upon the taking of their drug of choice. Turning to the more exotic, a drug such as LSD may alter the way the world looks to us; it may even inspire thoughts of God. Adding to the purely scientific questions which confront us are the ways in which our society chooses to respond to the presence of psychoactive drugs. Should they be banned and their users sent to prison, tolerated as a reflection of man's eternal search for an escape from anxiety, pain, and the monotony of daily life, or celebrated as therapeutically useful agents? Our Love Affair with Drugs is written for experts and novices alike. There are stories of, for example, how Timothy Leary caused the repeal of the Marijuana Tax Act of 1937. Readers will learn of the transformation by Sir Charles Locock of a drug intended to dampen female sexual activity into the first effective drug for the treatment of the ancient disease of epilepsy. Alexander Shulgin's love of psychoactive drugs and his unconventional research practices illuminate the story of methylenedioxymethamphetamine, a.k.a. Ecstasy, a drug now likely to find value in treating veterans and others suffering post-traumatic distress disorder. Winter links the excitement of drug discovery with the very practical matter of balancing the benefits and risks of these drugs.